Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Alfa Cytology is leading the way in the advancement of sophisticated immunotherapies for the treatment of leukemia. With a steadfast commitment to innovation, we tirelessly explore groundbreaking treatments for leukemia. Our comprehensive support to researchers and pharmaceutical companies In the realm of therapeutic interventions for leukemia is aimed at developing an effective vaccine against leukemia and finding a solution.
Despite the notable advancements achieved in chemotherapy and targeted therapy, the challenge of relapse remains a significant concern. Consequently, there is increasing interest in leukemia vaccine development, which aims to elicit cellular immune responses against residual leukemia stem cells. This innovative approach shows considerable potential, particularly for older individuals afflicted with relapsed acute myeloid leukemia, offering them a novel treatment alternative.
Fig. 1. Main mechanisms for vaccine-based immunotherapy production and function in acute myeloid leukemia (AML). (Barbullushi, K. et al., 2022)
After immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapy, and antibody-drug conjugates (ADCs), therapeutic cancer vaccines are expected to be the next standard-of-care innovation in cancer care. Alfa Cytology provides comprehensive therapeutic vaccine development services, including but not limited to the following.
We offer comprehensive support in developing vaccine strategies for peptide vaccine antigens and facilitate the vaccine development process for leukemia. Leukemia antigens are the basis for the design of these vaccines, which include Wilms tumor 1 (WT1), mucin 1 protein (MUC1), receptor for hyaluronic acid-mediated motility (RHAMM), and proteinase 3 (PR3).
We understand that different needs require tailored approaches. We prioritize key considerations such as the selection of suitable leukemia antigens and immunogenic adjuvants, optimization and modification of leukemia vaccine. We aim to provide comprehensive solutions to meet your specific requirements in developing leukemia vaccines.
Our services include genetically modifying leukemia cells to express co-stimulatory and immunostimulatory cytokines ligands to solve your problem of low immunogenicity of leukemia cell vaccines during vaccine development.
| CD80-expressing leukemia cells | Through the application of genetic engineering techniques, we can modify leukemia cells at the genetic level, enabling the production of leukemia cells that express CD80. |
| CD40-expressing leukemia cells | Through genetic modification, we have successfully engineered leukemia cells to express CD80, opening up a new avenue for chronic lymphocytic leukemia treatment. |
| Dendritic cells | Our institute provides specialized services for the differentiation of leukemia cells into cells resembling antigen-presenting cells, catering specifically to research in the domain of acute myeloid leukemia immunotherapy. |
| GM-CSF secreting leukemia cells | The strategy of genetically modifying leukemia cells to secrete GM-CSF offers a novel solution to enhance the immunogenicity of leukemia cell vaccines. |
Our organization provides extensive solutions for the advancement of DNA vaccines, facilitating the fulfillment of diverse vaccine needs and expediting the progression of your leukemia DNA vaccine development project towards clinical trials.
Alfa Cytology has focused on cancer vaccines for many years, particularly developing leukemia vaccines. We are committed to providing the highest quality service and support to developers of leukemia vaccine treatments. Contact our team and let’s accelerate the research and development of a vaccine for leukemia together.
Reference